Researchers at Johns Hopkins University have suggested that psilocybin, which is found in hallucinogenic mushrooms, be reclassified from a Schedule I drug, with no known medical benefit, to a Schedule IV drug, which is akin to prescription sleeping pills.CreditCreditAnthony Devlin/PA Wire, via Associated Press
Researchers from Johns Hopkins University have recommended that psilocybin, the active compound in hallucinogenic mushrooms, be reclassified for medical use, potentially paving the way for the psychedelic drug to one day treat depression and anxiety and help people stop smoking.
The suggestion to reclassify psilocybin from a Schedule I drug, with no known medical benefit, to a Schedule IV drug, which is akin to prescription sleeping pills, was part of a review to assess the safety and abuse of medically administered psilocybin.
Before the Food and Drug Administration can be petitioned to reclassify the drug, though, it has to clear extensive study and trials, which can take more than five years, the researchers wrote.
Read from original article